Role of Stenting for Intracranial Atherosclerosis in the Post-SAMMPRIS Era

Table 1

Summary of endovascular stenting series for the treatment of intracranial atherosclerosis published after SAMMPRIS.

Series	Year	Type of stent	Number of patients (lesions)	Minimum arterial stenosis	Technical success rate	Mean/median clinical follow-up duration (months)	Rate of postprocedural ischemia (ipsilateral)	Rate of postprocedural ischemia (all)	Rate of symptomatic in-stent restenosis
Gandini et al. [20]	2013	Wingspan	21 (42)	70%	100%	20	4.8%	4.8%	0
Jin et al. [33]	2013	Multiple^1	226 (233)	NR	NR	39	11.6%	11.6%	5.2%
Park et al. [18]	2013	Cypher	11 (11)	50%	100%	67	0	0	0
Rohde et al. [21]	2013	Multiple^2	100 (100)	50%	94.0%	1	NR	25%	NR
Yu et al. [17]	2013	Wingspan	95 (95)	70%	93.7%	41	3.1% in 30 days, 0% from 30 days to 1 year	9.5% in 1 year	NR
Zhang et al. [19]	2013	Wingspan	61 (61)	70%	98.4%	24	10.0%	11.7%	3.3%
Jiang et al. [28]	2012	Multiple^3	637 (670)	50%	94.6%	NR	5.8% at 30 days, 13.7% overall	5.8% at 30 days, 13.7% overall	11.1%
Kim et al. [22]	2012	Multiple^4	77 (85)	50%	87.1%	29	7.7%	9.2%	3.1%
Kurre et al. [31]	2012	Multiple^5	397 (409)	50%	98.0%		NR	11.6%	NR
Li et al. [30]	2012	Wingspan	30 (31)	70%	100%	18	13.3%	16.7%	5.3%
Mohammadian et al. [24]	2012	Multiple^6	34 (34)	70%	97.0%	15	2.9%	5.8%	0
Tarlov et al. [26]	2012	Multiple^7	41 (41)	50%	100%	14	NR	20.0%	7.5%
Vajda et al. [29]	2012	Enterprise	189 (209)	50%	99.5%	7	2.3%	7.7%	2.3%
Vajda et al. [23]	2012	Coroflex Please	95 (106)	50%	93.4%	16	1.9%	3.8% in 30 days, 0.9% after 30 days	0
Yu et al. [27]	2012	Wingspan	57 (57)	50%	93.0%	NR	NR	8.8%	NR
Zhang et al. [25]	2012	Wingspan	53 (53)	50%	98.1%	18	6.0%	10.0%	4.0%
Costalat et al. [32]	2011	Wingspan	60 (63)	50%	95.2%	13	6.3%	6.3%	2.0%
Park et al. [34]	2011	FlexMaster	12 (14)	70%	100%	9	0	0	0

NR: not reported.
1Multiple stents were used in this study including Wingspan (Boston Scientific), Apollo (MicroPort Medical), and coronary balloon-expandable stents.
2Multiple stents were used in this study including AVE (Medtronic), Neurolink (Guidant), Neuroform (Boston Scientific), and Wingspan (Boston Scientific) stents.
3Multiple stents were used in this study including Vision (Abbott), Mini-Vision (Abbott), Penta (Abbott), Taxus Express (Boston Scientific), Cypher (Cordis Corp), S70 (Medtronic), Driver (Medtronic), Apollo (MicroPort Medical), BiodivYsio (Biocompatibles), and Wingpan (Boston Scientific) stents.
4Multiple stents were used in this study including Endeavor (Medtronic), Vision (Abbott), FlexMaster (Abbott), Arthos pico (AMG International), Neuroform (Boston Scientific), Tsunami (Terumo), and Driver (Medtronic) stents.
5Multiple stents were used including Wingspan (Boston Scientific), LEO (BALT Extrusion), Neuroform (Boston Scientific), Enterprise (Cordis Corp), Xpert (Abbott), Pharos (Micrus), BOA (BALT Extrusion), Apollo (MicroPort Medical), Arthos (AMG), AVE S660 and S670 (Medtronic) BX Sonic and Velocity (Cordis Corp), Cerebrence (Medtronic), Coroflex blue (Braun), Driver (Medtronic), Endeavour (Medtronic), FlexMaster (Abbott), INX (Medtronic), Lekton Motion (Biotronik), Multi-Link (Abbott), S7 (Medtronic), Taxus Express and Liberte (Boston Scientific), Tecnic carbostent (Sorin Biomedica), and Tsunami Gold (Terumo) stents.
6Multiple stents were used including balloon-mounted, coronary bare metal stent for internal carotid artery stenosis, and self-expanding stents for middle cerebral artery stenosis.
7Multiple stents were used including Wingspan (Boston Scientific), AVE (Medtronic), ACS, Voyager (Abbott), Vision (Abbott), Palmaz-Schatz (Cordis Corp), Multilink (Abbott), and other Guidant and Medtronic stents.